2022
Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617
Peng L, Hu Y, Mankowski MC, Ren P, Chen RE, Wei J, Zhao M, Li T, Tripler T, Ye L, Chow RD, Fang Z, Wu C, Dong MB, Cook M, Wang G, Clark P, Nelson B, Klein D, Sutton R, Diamond MS, Wilen CB, Xiong Y, Chen S. Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617. Nature Communications 2022, 13: 1638. PMID: 35347138, PMCID: PMC8960874, DOI: 10.1038/s41467-022-29288-3.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Authentic SARS-CoV-2Effective therapeutic optionPotent SARS-CoV-2SARS-CoV-2 variantsVariants of concernRepertoire of therapeuticsBreakthrough infectionsTherapeutic optionsMultiple vaccinesPathogen SARS-CoV-2Delta variantB cellsPotent efficacyHumanized antibodyDistinct epitopesBispecific antibodiesOriginal virusSpike receptorStrong inhibitory activityMonoclonal antibodiesAntibodiesStrong potencyLead clonesLead antibodies
2021
Functional landscape of SARS-CoV-2 cellular restriction
Martin-Sancho L, Lewinski MK, Pache L, Stoneham CA, Yin X, Becker ME, Pratt D, Churas C, Rosenthal SB, Liu S, Weston S, De Jesus PD, O'Neill AM, Gounder AP, Nguyen C, Pu Y, Curry HM, Oom AL, Miorin L, Rodriguez-Frandsen A, Zheng F, Wu C, Xiong Y, Urbanowski M, Shaw ML, Chang MW, Benner C, Hope TJ, Frieman MB, García-Sastre A, Ideker T, Hultquist JF, Guatelli J, Chanda SK. Functional landscape of SARS-CoV-2 cellular restriction. Molecular Cell 2021, 81: 2656-2668.e8. PMID: 33930332, PMCID: PMC8043580, DOI: 10.1016/j.molcel.2021.04.008.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, CDBinding SitesCell Line, TumorChlorocebus aethiopsEndoplasmic ReticulumGene Expression RegulationGolgi ApparatusGPI-Linked ProteinsHEK293 CellsHost-Pathogen InteractionsHumansImmunity, InnateInterferon Regulatory FactorsInterferon Type IMolecular Docking SimulationProtein BindingProtein Conformation, alpha-HelicalProtein Conformation, beta-StrandProtein Interaction Domains and MotifsSARS-CoV-2Signal TransductionVero CellsViral ProteinsVirus InternalizationVirus ReleaseVirus ReplicationConceptsAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSARS-CoV-1 infectionSyndrome coronavirus 2 infectionSevere coronavirus disease 2019SARS-CoV-2 infectionCoronavirus 2 infectionInnate immune controlCoronavirus disease 2019Potential therapeutic strategySARS-CoV-2BST2/tetherinImmune controlSet of ISGsDisease 2019Host determinantsTherapeutic strategiesViral infectionAntiviral ISGsDisease severityViral replicationInterferon responseViral entryIFN controlInfection